These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15609120)

  • 41. Consistency of new drug pricing in Korea: Bridging variations among personnel in price negotiations.
    Kwon HY; Kim J
    Health Policy; 2020 Sep; 124(9):965-970. PubMed ID: 32660816
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence.
    Kaló Z; Muszbek N; Bodrogi J; Bidló J
    Health Policy; 2007 Mar; 80(3):402-12. PubMed ID: 16730848
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multi-indication and Combination Pricing and Reimbursement of Pharmaceuticals: Opportunities for Improved Health Care through Faster Uptake of New Innovations.
    Persson U; Norlin JM
    Appl Health Econ Health Policy; 2018 Apr; 16(2):157-165. PubMed ID: 29470774
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Insight into recent reforms and initiatives in Austria: implications for key stakeholders.
    Godman B; Bucsics A; Burkhardt T; Haycox A; Seyfried H; Wieninger P
    Expert Rev Pharmacoecon Outcomes Res; 2008 Aug; 8(4):357-71. PubMed ID: 20528343
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differences in the cost of antidepressants across state Medicaid programs.
    Kelton CM; Rebelein RP; Heaton PC; Ferrand Y; Guo JJ
    J Ment Health Policy Econ; 2008 Mar; 11(1):33-47. PubMed ID: 18424875
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The impact of decentralised drug-budgets in Sweden - a survey of physicians' attitudes towards costs and cost-effectiveness.
    Jansson S; Anell A
    Health Policy; 2006 May; 76(3):299-311. PubMed ID: 16046026
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The impact of cost sharing of prescription drug expenditures on health care utilization by the elderly: own- and cross-price elasticities.
    Li X; Guh D; Lacaille D; Esdaile J; Anis AH
    Health Policy; 2007 Aug; 82(3):340-7. PubMed ID: 17134787
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Changes over 5 years in utilization of dental care by a Swedish age cohort.
    Ståhlnacke K; Söderfeldt B; Unell L; Halling A; Axtelius B
    Community Dent Oral Epidemiol; 2005 Feb; 33(1):64-73. PubMed ID: 15642048
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The End of the International Reference Pricing System?
    Persson U; Jönsson B
    Appl Health Econ Health Policy; 2016 Feb; 14(1):1-8. PubMed ID: 26112982
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The impact of China's retail drug price control policy on hospital expenditures: a case study in two Shandong hospitals.
    Meng Q; Cheng G; Silver L; Sun X; Rehnberg C; Tomson G
    Health Policy Plan; 2005 May; 20(3):185-96. PubMed ID: 15840634
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Reform of Japan's NTP and its technical perspectives].
    Mori T
    Kekkaku; 2004 Oct; 79(10):587-604. PubMed ID: 15631111
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of budget impact in drug reimbursement decisions.
    Cohen JP; Stolk E; Niezen M
    J Health Polit Policy Law; 2008 Apr; 33(2):225-47. PubMed ID: 18325899
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of New Drug Accessibility and Price Between Japan and Major European Countries.
    Takayama A; Narukawa M
    Ther Innov Regul Sci; 2017 Sep; 51(5):604-611. PubMed ID: 30231682
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recent Pricing Negotiations on Innovative Medicines Pilot in China: Experiences, Implications, and Suggestions.
    Li H; Liu GG; Wu J; Wu JH; Dong CH; Hu SL
    Value Health Reg Issues; 2018 May; 15():133-137. PubMed ID: 29705645
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The merry-go-round of approval, pricing and reimbursement of drugs against the Hepatitis C virus infection in Spain.
    Campillo-Artero C; Garcia-Armesto S; Bernal-Delgado E
    Health Policy; 2016 Sep; 120(9):975-81. PubMed ID: 27460522
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Drug prices in Switzerland: European comparison of "comfort" drugs].
    Vogt N; Morabia A; Dayer P
    Schweiz Med Wochenschr; 1993 Nov; 123(47):2251-4. PubMed ID: 8272798
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evolution of drug reimbursement in Canada: the Pan-Canadian Pharmaceutical Alliance for new drugs.
    Husereau D; Dempster W; Blanchard A; Chambers J
    Value Health; 2014 Dec; 17(8):888-94. PubMed ID: 25498784
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Pharmacoeconomic Evaluation Process in Ireland.
    McCullagh L; Barry M
    Pharmacoeconomics; 2016 Dec; 34(12):1267-1276. PubMed ID: 27473640
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe.
    Wettermark B; Godman B; Andersson K; Gustafsson LL; Haycox A; Bertele V
    Pharmacoeconomics; 2008; 26(7):537-50. PubMed ID: 18563945
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Progress on drug pricing negotiations in China.
    Tang M; Song P; He J
    Biosci Trends; 2020 Jan; 13(6):464-468. PubMed ID: 31875587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.